Unjoni Ewropea - Malti - EMA (European Medicines Agency)

elanco gmbh - monensin (bħala monensin sodium) - mediċini għall-prevenzjoni u/jew it-trattament tal-acetonemia - baqar (baqar u erħiet) - għat-tnaqqis fl-inċidenza ta 'ketożi fil-baqra tal-ħalib peri-parturient / għoġġiela li hija mistennija li tiżviluppa ketożi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfoma, b-cell - aġenti antineoplastiċi - polivy flimkien ma bendamustine u rituximab huwa indikat għall-kura ta ' pazjenti adulti b'reġgħet tfaċċat/refrattarja b kbira mxerrda-cell lymphoma (dlbcl) li mhumiex kandidati għall-trapjant ta'ċelloli staminali ematopojetiċi. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

csl behring gmbh - immunoglobulina normali umana (scig) - sindromi ta 'defiċjenza immunoloġika - sera immuni u immunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - aġenti antineoplastiċi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - toxoid tad-difterite, toxoid tat-tetnu, ta ' bordetella pertussis, l-epatite b ippurifikat (rdna), haemophilus influenzae tat-tip b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; diphtheria - vaċċini - quintanrix huwa indikat għall-immunisation primarji tat-trabi (matul l-ewwel sena tal-ħajja) kontra diphtheria, tetanus, pertussis, epatite b u invażivi marda kkawżata mill-influwenza Ħemofillika tip b u għall-booster immunisation ta ' tfal matul il- it-tieni sena tal-ħajja. l-użu ta 'quintanrix għandu jiġi determinat fuq il-bażi ta' rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicin hydrochloride - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - aġenti antineoplastiċi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - aġenti antitrombotiċi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - oritavancin (diphosphate) - soft tissue infections; skin diseases, bacterial - antibatteriċi għal użu sistemiku, - tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and paediatric patients aged 3 months and older (see sections 4. 2, 4. 4 u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - sinusitis; tonsillitis; bronchitis, chronic; pharyngitis; community-acquired infections; pneumonia, bacterial - antibatteriċi għal użu sistemiku, - meta tippreskrivi ketek, għandha tingħata konsiderazzjoni lill-gwida uffiċjali dwar l-użu xieraq ta 'aġenti antibatteriċi u l-prevalenza lokali ta' reżistenza. ketek huwa indikat għall-kura ta 'l-infezzjonijiet li ġejjin:f'pazjenti ta' 18-il sena u oldercommunity-pnewmonja akkwiżita, ħfief jew moderati. meta jiġu ttrattati infezzjonijiet ikkawżati minn magħrufa jew suspettati beta-lactam u / jew makrolidi-razez reżistenti (skond il-passat mediku tal-pazjenti jew nazzjonali u / jew reġjonali tar-reżistenza tad-data) koperti mill-batterja tal-ispettru tal-telithromycin:taħrix akut tal-bronkite kronika;sinusite akuta;f'pazjenti ta '12-il sena u oldertonsillitis / farinġite ikkawżata minn streptococcus pyogenes bħala alternattiva meta l-antibijotiċi beta-lactam ma jkunux adatti f'pajjiżi / reġuni bi prevalenza sinifikanti ta' reżistenti għall-s. pyogenes, meta medjati b'ermtr jew bejn it.